Jazz Pharmaceuticals plc

JAZZNASDAQHealthcare● Active

$233.95

$-4.62(-1.94%)

Market Cap$14.7B

P/E Ratio—

52W High$243.32

52W Low$105

Avg Volume916K

Open$238.65

Beta0.33

Free Cash Flow Financials Revenue

Jazz Pharmaceuticals plc (JAZZ) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

JAZZ · free cash flow · updated Jun 8, 2026

Core FCF metrics

JAZZ · FCF · TTM · margin & CAGR

Free cash flow was $1.30B for FY2025 (fiscal year ending 2025-12-31), down 3.8% year-over-year The FCF margin was 30.4%. Five-year CAGR stands at +20.0%.

FY2025 Free Cash Flow$1.30B▼ -3.8% YoY

Trailing 12M (TTM)$1.25Btrailing 4 quarters sum

FCF Margin30.4%$1.30B ÷ revenue

3-Year CAGR+18.8%FY2022 → FY2025

5-Year CAGR+20.0%FY2020 → FY2025

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

JAZZ · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$1.36B(59M)$1.30B▼ 3.8%30.4%

FY2024$1.40B(48M)$1.35B▲ +26.2%33.1%

FY2023$1.09B(24M)$1.07B▲ +38.0%27.9%

FY2022$1.27B(498M)$773.8M▲ +5.6%21.1%

FY2021$778.5M(46M)$733.0M▲ +40.9%23.7%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

JAZZ · P/FCF · FCF yield · FCF per share

Jazz Pharmaceuticals plc (JAZZ) trades at a FCF yield of 8.30% and a price-to-free-cash-flow ratio of 11.5x. FCF per share stands at $20.43, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

8.30%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$20.43

TTM FCF ÷ Shares Outstanding

Price / FCF

x11.5

Share Price ÷ FCF per Share

EV / FCF (TTM)

x14.9

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

JAZZ · cash flow statement · operating / investing / financing

For FY2025, Jazz Pharmaceuticals plc generated $1.36B in operating cash flow and spent 59M in capital expenditures, yielding $1.30B in free cash flow.

Operating Activities

+$1.36B

Cash from core business operations

2025-12-31

Investing Activities

−$1.51B

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$873.4M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($1.36B) − |CapEx| (59M) = FCF ($1.30B)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

JAZZ vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Jazz Pharmaceuticals plcYOU

JAZZ

$1.30B-3.8%30.4%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Jazz Pharmaceuticals plc (JAZZ) reported free cash flow of $1.30B for FY2025 (fiscal year ending 2025-12-31), down 3.8% year-over-year. The FCF margin was 30.4%.

Based on available data, Jazz Pharmaceuticals plc has maintained positive free cash flow for at least 15 fiscal year(s). FCF peaked at $1.35B in FY2024. The 5-year CAGR stands at +20.0%.

Jazz Pharmaceuticals plc's FCF yield is 8.30% and price-to-FCF ratio is 11.5x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

JAZZ free cash flow · 8 questions

Jazz Pharmaceuticals plc free cash flow was $1.30B for FY2025, down 3.8% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $1.25B.

JAZZ free cash flowJAZZ FCFJAZZ FCF 2025JAZZ free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Jazz Pharmaceuticals plc · Jazz Pharmaceuticals plc SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026